Committee Chair
Abstract
Children develop a rather different spectrum of non-Hodgkin’s lymphoma (NHL) than adults, consisting largely of mature B-cell-derived malignancies (Burkitt’s lymphoma & leukemia, diffuse large B-cell lymphoma, and primary mediastinal large B-cell lymphoma), but also anaplastic large cell lymphomas, and immature malignancies derived from both cell types (T- or B-cell lymphoblastic lymphoma). Other, rarer NHL entities are also seen and include pediatric-type follicular lymphoma, pediatric nodal marginal zone lymphoma, primary central nervous system lymphomas, and non-anaplastic peripheral T-cell lymphomas. In general, NHL diagnosed in children and adolescents has a good prognosis with over 90% of children being cured, although treatment remains a combination of cytotoxic agents with significant side-effects, and children that relapse largely have a poor prognosis. With the advent of prognostic biomarkers and a deeper understanding of the biology of this class of malignancies, novel treatment approaches are being tested in collaborative trials with the hope that they will improve the outlook for children, adolescents and young adults with NHL.
Scientific aims
- Enhancement of diagnostics and therapy of children and AYAs with NHL
- Assessment of outcomes and prognosis of children and AYAs with NHL
- Diagnostic and therapy guidelines for rare NHL entities
- Pre-existing disorders and risk of the development of NHL
- Cooperation with other societies (i.e., EICNHL, other i-BFM Committees, and SIOPE)
Ongoing clinical trials
-
EICNHL trial
ALCL-VBL study in SR ALK-pos. ALCL
-
EICNHL/i-BFM trial
LBL 2018 study in lymphoblastic lymphoma
-
NHL-BFM and NOPHO trial
B-NHL 2013 study in mature B-cell neoplasms